Protein Labeling and Crosslinking by Covalent Aptamers

共价适体的蛋白质标记和交联

基本信息

项目摘要

PROJECT SUMMARY The overall goal of this proposal is to develop a fundamentally new class of oligonucleotide agents – covalent aptamers – that will have a major impact on nucleic acid-based reagents and therapeutics. Covalent aptamers will be an enabling methodology behind new aptamer applications and will provide new solutions to persistent limitations of this compound class. Aptamers are engineered oligonucleotides that bind protein targets and have found applications in a multitude of areas, including therapeutics, diagnostics, drug delivery, and imaging. They bind their targets with affinity and specificity that rivals those of antibodies, while displaying lower production cost, higher production consistency, and the ability to easily introduce chemical modifications. Capitalizing on the ability to amplify and sequence nucleic acids, aptamers are being generated through SELEX, a powerful in vitro selection process. Our central hypothesis is that the formation of a covalent bond between an aptamer – or a functional motif delivered by the aptamer – and its target protein will provide unprecedented residence time, increase nuclease stability (or obviate the need for it), and facilitate aptamer selection. Furthermore, covalent bond formation enables new applications based on the aptamer platform. The following aims will test this hy- pothesis. Aim 1: The chemistry of covalent aptamers. To gain a comprehensive understanding of the design principles behind covalent aptamers and to enable broad applicability, we will explore their chemistry based on our promising preliminary results. We will explore applications in antibody drug conjugate assembly, as well as catalytic covalent bond formation. Aim 2: Cell-based applications of covalent aptamers. We will develop several applications that are enabled by covalent aptamers and that showcase their utility as chemical biology probes. We are focusing on cell-surface proteins due to the rich collection of aptamers that have been reported. Aim 3: Selection of covalent aptamers. For the de novo generation of covalent aptamers capable of selectively cross- linking to any chosen protein target without prior sequence and/or structural information, we will develop a gen- eralized in vitro selection process that adds distinct advantages to traditional SELEX.
项目摘要 该提案的总体目标是开发一种全新的寡核苷酸试剂-共价寡核苷酸。 适体-这将对基于核酸的试剂和疗法产生重大影响。共价适体 将是新适体应用背后的一种使能方法,并将为持久性 这个复合类的局限性。适体是工程化的寡核苷酸,其结合蛋白质靶标并具有 在包括治疗学、诊断学、药物递送和成像在内的众多领域中找到了应用。他们 与靶点结合的亲和力和特异性与抗体相当, 成本、更高的生产一致性以及容易引入化学改性的能力。充分利用 核酸扩增和测序的能力,适体是通过SELEX产生的,一种强大的插入技术, 体外选择过程。我们的中心假设是,适体-或 由适体及其靶蛋白递送的功能基序将提供前所未有的停留时间, 增加核酸酶稳定性(或减少对它的需要),并促进适体选择。此外,共价 键的形成使得基于适体平台的新应用成为可能。以下目标将检验这一假设- 假设目的1:共价适体的化学。全面了解设计 共价适体背后的原理,并使广泛的适用性,我们将探索他们的化学基础上, 我们有希望的初步结果。我们将探索抗体药物偶联物组装中的应用,以及 催化共价键形成。目的2:共价适体的基于细胞的应用。我们将开发几个 这些应用是由共价适体实现的,并展示了它们作为化学生物学探针的实用性。 我们专注于细胞表面蛋白质,因为已经报道了丰富的适体集合。目标三: 共价适体的选择。对于能够选择性交叉的共价适体的从头生成, 连接到任何选定的蛋白质靶点,而无需事先的序列和/或结构信息,我们将开发一个基因, 一种成熟的体外选择过程,为传统的SELEX增加了明显的优势。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alexander Deiters其他文献

Alexander Deiters的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alexander Deiters', 18)}}的其他基金

Protein Labeling and Crosslinking by Covalent Aptamers
共价适体的蛋白质标记和交联
  • 批准号:
    10391640
  • 财政年份:
    2022
  • 资助金额:
    $ 35.65万
  • 项目类别:
Conditional Control of Drug Function Through α-Boryl Ether Oxidation
通过α-硼基醚氧化条件控制药物功能
  • 批准号:
    9895812
  • 财政年份:
    2019
  • 资助金额:
    $ 35.65万
  • 项目类别:
Conditional Control of Drug Function Through α-Boryl Ether Oxidation
通过α-硼基醚氧化条件控制药物功能
  • 批准号:
    9750473
  • 财政年份:
    2019
  • 资助金额:
    $ 35.65万
  • 项目类别:
Conditional Control of Drug Function Through α-Boryl Ether Oxidation
通过α-硼基醚氧化条件控制药物功能
  • 批准号:
    10380804
  • 财政年份:
    2019
  • 资助金额:
    $ 35.65万
  • 项目类别:
Optical Control of Translation and Gene Editing in Zebrafish Embryos
斑马鱼胚胎翻译和基因编辑的光学控制
  • 批准号:
    9357624
  • 财政年份:
    2016
  • 资助金额:
    $ 35.65万
  • 项目类别:
High-Throughput Assay for the Discovery of Small Molecule Inhibitors of microRNA
用于发现 microRNA 小分子抑制剂的高通量检测
  • 批准号:
    8299685
  • 财政年份:
    2010
  • 资助金额:
    $ 35.65万
  • 项目类别:
Switchable Systems for Spatio-Temporal Control of Gene Expression in Zebrafish
用于斑马鱼基因表达时空控制的可切换系统
  • 批准号:
    8004512
  • 财政年份:
    2010
  • 资助金额:
    $ 35.65万
  • 项目类别:
High-Throughput Assay for the Discovery of Small Molecule Inhibitors of microRNA
用于发现 microRNA 小分子抑制剂的高通量检测
  • 批准号:
    8050335
  • 财政年份:
    2010
  • 资助金额:
    $ 35.65万
  • 项目类别:
Switchable Systems for Spatio-Temporal Control of Gene Expression in Zebrafish
用于斑马鱼基因表达时空控制的可切换系统
  • 批准号:
    7465438
  • 财政年份:
    2007
  • 资助金额:
    $ 35.65万
  • 项目类别:
Switchable Systems for Spatio-Temporal Control of Gene Expression in Zebrafish
用于斑马鱼基因表达时空控制的可切换系统
  • 批准号:
    7845740
  • 财政年份:
    2007
  • 资助金额:
    $ 35.65万
  • 项目类别:

相似海外基金

Double Incorporation of Non-Canonical Amino Acids in an Animal and its Application for Precise and Independent Optical Control of Two Target Genes
动物体内非规范氨基酸的双重掺入及其在两个靶基因精确独立光学控制中的应用
  • 批准号:
    BB/Y006380/1
  • 财政年份:
    2024
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Research Grant
Quantifying L-amino acids in Ryugu to constrain the source of L-amino acids in life on Earth
量化 Ryugu 中的 L-氨基酸以限制地球生命中 L-氨基酸的来源
  • 批准号:
    24K17112
  • 财政年份:
    2024
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular recognition and enantioselective reaction of amino acids
氨基酸的分子识别和对映选择性反应
  • 批准号:
    23K04668
  • 财政年份:
    2023
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Basic research toward therapeutic strategies for stress-induced chronic pain with non-natural amino acids
非天然氨基酸治疗应激性慢性疼痛策略的基础研究
  • 批准号:
    23K06918
  • 财政年份:
    2023
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular mechanisms how arrestins that modulate localization of glucose transporters are phosphorylated in response to amino acids
调节葡萄糖转运蛋白定位的抑制蛋白如何响应氨基酸而被磷酸化的分子机制
  • 批准号:
    23K05758
  • 财政年份:
    2023
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Design and Synthesis of Fluorescent Amino Acids: Novel Tools for Biological Imaging
荧光氨基酸的设计与合成:生物成像的新工具
  • 批准号:
    2888395
  • 财政年份:
    2023
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Studentship
Collaborative Research: RUI: Elucidating Design Rules for non-NRPS Incorporation of Amino Acids on Polyketide Scaffolds
合作研究:RUI:阐明聚酮化合物支架上非 NRPS 氨基酸掺入的设计规则
  • 批准号:
    2300890
  • 财政年份:
    2023
  • 资助金额:
    $ 35.65万
  • 项目类别:
    Continuing Grant
Structurally engineered N-acyl amino acids for the treatment of NASH
用于治疗 NASH 的结构工程 N-酰基氨基酸
  • 批准号:
    10761044
  • 财政年份:
    2023
  • 资助金额:
    $ 35.65万
  • 项目类别:
Lifestyle, branched-chain amino acids, and cardiovascular risk factors: a randomized trial
生活方式、支链氨基酸和心血管危险因素:一项随机试验
  • 批准号:
    10728925
  • 财政年份:
    2023
  • 资助金额:
    $ 35.65万
  • 项目类别:
Single-molecule protein sequencing by barcoding of N-terminal amino acids
通过 N 端氨基酸条形码进行单分子蛋白质测序
  • 批准号:
    10757309
  • 财政年份:
    2023
  • 资助金额:
    $ 35.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了